Table 3.
A: Surrounding Tumor Tissue Markers by Disease Type | |||||
---|---|---|---|---|---|
IBC Cases (N=45) |
Treated IDC Cases (N=24) |
Untreated IDC Cases (N=27) |
P-Value | ||
pS6 | 0 | 0 | 0 | 4 (14.8%) | <0.0001^ |
1+ | 5 (11.6%) | 2 (8.7%) | 13 (48.2%) | ||
2+ | 37 (86.1%) | 19 (82.6%) | 10 (37%) | ||
3+ | 1 (2.3%) | 2 (8.7%) | 0 | ||
No normal tissue | |||||
Analysis N/A | 2 | 1 | |||
pJAK2 | 0 | 2 (4.8%) | 1 (4.2%) | 20 (80%) | <0.0001^ |
1+ | 21 (50.0%) | 9 (37.5%) | 5 (20%) | ||
2+ | 19 (45.2%) | 13 (54.2%) | 0 | ||
3+ | 0 | 1 (4.2%) | 0 | ||
No normal tissue | |||||
Analysis N/A | 3 | 2 | |||
pSTAT3 | 0 | 18 (45.0%) | 9 (37.5%) | 24 (92.3%) | 0.0001^ |
1+ | 19 (47.5%) | 13 (54.2%) | 2 (7.7%) | ||
2+ | 3 (7.5%) | 2 (8.3%) | 0 | ||
No normal tissue | |||||
Analysis N/A | 5 | 1 | |||
IL6 | 0 | 2 (4.8%) | 3 (12.5%) | 4 (15.4%) | 0.0174^ |
1+ | 30 (71.4%) | 15 (62.5%) | 22 (84.6%) | ||
2+ | 10 (23.8%) | 6 (25%) | 0 | ||
No normal tissue | |||||
Analysis N/A | 3 | 1 | |||
CD68* | Median (range) | 40 (4–100) | 57.5 (10–100) | 80 (30–105) | <.0001^^ |
No Tumor Available | 5 | ||||
No Tissue Available | |||||
CD163* | Median (range) | 28 (3–80) | 40 (18–75) | 40 (6–90) | 0.0013^^ |
No Tumor Available | 4 | ||||
No Tissue Available |
B: Pairwise Comparisons of Expression Levels in Tumor Tissue – P-Values (Pairwise Comparisons of Table 3A) | |||
---|---|---|---|
IBC vs Treated IDC |
IBC vs Untreated IDC |
Treated IDC vs Untreated IDC |
|
pS6^ | 0.4889 | <.0001 | 0.0002 |
pJAK2^ | 0.4945 | <.0001 | <.0001 |
pSTAT3^ | 0.8569 | 0.0002 | <.0001 |
IL6^ | 0.4915 | 0.0065 | 0.0226 |
CD68^^ | 0.0051 | <.0001 | 0.0005 |
CD163^^ | 0.0017 | 0.0034 | 0.7539 |
Fisher's Exact Test
Kruskal-Wallis non parametric analysis of variance test
p<0.0167 is considered significant
Fisher’s Exact Test
Wilcoxon Rank Sum Test